Literature DB >> 23429537

Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.

Kazutoyo Miura1, Raul Herrera, Ababacar Diouf, Hong Zhou, Jianbing Mu, Zonghui Hu, Nicholas J MacDonald, Karine Reiter, Vu Nguyen, Richard L Shimp, Kavita Singh, David L Narum, Carole A Long, Louis H Miller.   

Abstract

Apical membrane antigen 1 (AMA1) is a leading vaccine candidate, but the allelic polymorphism is a stumbling block for vaccine development. We previously showed that a global set of AMA1 haplotypes could be grouped into six genetic populations. Using this information, six recombinant AMA1 proteins representing each population were produced. Rabbits were immunized with either a single recombinant AMA1 protein or mixtures of recombinant AMA1 proteins (mixtures of 4, 5, or 6 AMA1 proteins). Antibody levels were measured by enzyme-linked immunosorbent assay (ELISA), and purified IgG from each rabbit was used for growth inhibition assay (GIA) with 12 different clones of parasites (a total of 108 immunogen-parasite combinations). Levels of antibodies to all six AMA1 proteins were similar when the antibodies were tested against homologous antigens. When the percent inhibitions in GIA were plotted against the number of ELISA units measured with homologous AMA1, all data points followed a sigmoid curve, regardless of the immunogen. In homologous combinations, there were no differences in the percent inhibition between the single-allele and allele mixture groups. However, all allele mixture groups showed significantly higher percent inhibition than the single-allele groups in heterologous combinations. The 5-allele-mixture group showed significantly higher inhibition to heterologous parasites than the 4-allele-mixture group. On the other hand, there was no difference between the 5- and 6-allele-mixture groups. These data indicate that mixtures with a limited number of alleles may cover a majority of the parasite population. In addition, using the data from 72 immunogen-parasite combinations, we mathematically identified 13 amino acid polymorphic sites which significantly impact GIA activities. These results could be a foundation for the rational design of a future AMA1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429537      PMCID: PMC3648006          DOI: 10.1128/IAI.01414-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; Solange Solmeheim Soulanoudjingar; José Francisco Fernandes; Béatrice Peggy Abossolo; Cornelia Conzelmann; Barbara Gaelle Nfono Ondo Methogo; Yannick Doucka; Arnaud Flamen; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Arlindo Nhamuave; Diana Quelhas; Quique Bassat; Sofia Mandjate; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Omar Juma; Mwanajaa Shomari; Kafuruki Shubis; Francisca Machera; Ali Said Hamad; Rose Minja; Ali Mtoro; Alma Sykes; Saumu Ahmed; Alwisa Martin Urassa; Ali Mohammed Ali; Grace Mwangoka; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Marc Christian Tahita; William Kaboré; Sayouba Ouédraogo; Yara Sandrine; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Chris Odero; Martina Oneko; Kephas Otieno; Norbert Awino; Jackton Omoto; John Williamson; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Otsyula Nekoye; Stacey Gondi; Allan Otieno; Bernhards Ogutu; Ruth Wasuna; Victorine Owira; David Jones; Agnes Akoth Onyango; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Jesse Gitaka; Charity Maingi; Trudie Lang; Ally Olotu; Benjamin Tsofa; Philip Bejon; Norbert Peshu; Kevin Marsh; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; Samuel Ayamba; Kingsley Kayan; Ruth Owusu-Ofori; David Dosoo; Isaac Asante; George Adjei; George Adjei; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Hassan Kilavo; Coline Mahende; Edwin Liheluka; Martha Lemnge; Thor Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Alex Agyekum; Larko Owusu; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Ruthendo Nkomo; Albans Msika; Allan Jumbe; Nelecy Chome; Dalitso Nyakuipa; Joseph Chintedza; W Ripley Ballou; Myriam Bruls; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Johan Vekemans; Terrell Carter; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2011-10-18       Impact factor: 91.245

2.  A field trial to assess a blood-stage malaria vaccine.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Matthew B Laurens; Amed Ouattara; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Idrissa Traore; Bourema Kouriba; Dapa A Diallo; Issa Diarra; Modibo Daou; Amagana Dolo; Youssouf Tolo; Mahamadou S Sissoko; Amadou Niangaly; Mady Sissoko; Shannon Takala-Harrison; Kirsten E Lyke; Yukun Wu; William C Blackwelder; Olivier Godeaux; Johan Vekemans; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; Darby Thompson; Tina Dube; Lorraine Soisson; Carter L Diggs; Brent House; David E Lanar; Sheetij Dutta; D Gray Heppner; Christopher V Plowe
Journal:  N Engl J Med       Date:  2011-09-15       Impact factor: 91.245

3.  Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya.

Authors:  Faith H A Osier; Gareth D Weedall; Federica Verra; Linda Murungi; Kevin K A Tetteh; Pete Bull; Bart W Faber; Ed Remarque; Alan Thomas; Kevin Marsh; David J Conway
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

4.  Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate.

Authors:  Matthew L Plassmeyer; Karine Reiter; Richard L Shimp; Svetlana Kotova; Paul D Smith; Darrell E Hurt; Brent House; Xiaoyan Zou; Yanling Zhang; Merrit Hickman; Onyinyechukwu Uchime; Raul Herrera; Vu Nguyen; Jacqueline Glen; Jacob Lebowitz; Albert J Jin; Louis H Miller; Nicholas J MacDonald; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

5.  In vitro growth-inhibitory activity and malaria risk in a cohort study in mali.

Authors:  Peter D Crompton; Kazutoyo Miura; Boubacar Traore; Kassoum Kayentao; Aissata Ongoiba; Greta Weiss; Safiatou Doumbo; Didier Doumtabe; Younoussou Kone; Chiung-Yu Huang; Ogobara K Doumbo; Louis H Miller; Carole A Long; Susan K Pierce
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

6.  Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.

Authors:  Kwadwo A Kusi; Bart W Faber; Vanessa Riasat; Alan W Thomas; Clemens H M Kocken; Edmond J Remarque
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

7.  Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.

Authors:  Kwadwo A Kusi; Edmond J Remarque; Vanessa Riasat; Vanessa Walraven; Alan W Thomas; Bart W Faber; Clemens H M Kocken
Journal:  Malar J       Date:  2011-07-04       Impact factor: 2.979

8.  Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

Authors:  Christopher J A Duncan; Susanne H Sheehy; Katie J Ewer; Alexander D Douglas; Katharine A Collins; Fenella D Halstead; Sean C Elias; Patrick J Lillie; Kelly Rausch; Joan Aebig; Kazutoyo Miura; Nick J Edwards; Ian D Poulton; Angela Hunt-Cooke; David W Porter; Fiona M Thompson; Ros Rowland; Simon J Draper; Sarah C Gilbert; Michael P Fay; Carole A Long; Daming Zhu; Yimin Wu; Laura B Martin; Charles F Anderson; Alison M Lawrie; Adrian V S Hill; Ruth D Ellis
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

9.  Worldwide incidence of malaria in 2009: estimates, time trends, and a critique of methods.

Authors:  Richard E Cibulskis; Maru Aregawi; Ryan Williams; Mac Otten; Christopher Dye
Journal:  PLoS Med       Date:  2011-12-20       Impact factor: 11.069

10.  Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.

Authors:  Kwadwo A Kusi; Bart W Faber; Alan W Thomas; Edmond J Remarque
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more
  28 in total

1.  Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Authors:  Karen S Harris; Christopher G Adda; Madhavi Khore; Damien R Drew; Antonina Valentini-Gatt; Freya J I Fowkes; James G Beeson; Sheetij Dutta; Robin F Anders; Michael Foley
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

2.  Vaccine design via nonnegative lasso-based variable selection.

Authors:  Zonghui Hu; Dean A Follmann; Kazutoyo Miura
Journal:  Stat Med       Date:  2015-02-02       Impact factor: 2.373

3.  Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria.

Authors:  Prakash Srinivasan; Emmanuel Ekanem; Ababacar Diouf; Michelle L Tonkin; Kazutoyo Miura; Martin J Boulanger; Carole A Long; David L Narum; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

4.  Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies.

Authors:  K Sony Reddy; Alok K Pandey; Hina Singh; Tajali Sahar; Amlabu Emmanuel; Chetan E Chitnis; Virander S Chauhan; Deepak Gaur
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

5.  Simulation of B cell affinity maturation explains enhanced antibody cross-reactivity induced by the polyvalent malaria vaccine AMA1.

Authors:  Sidhartha Chaudhury; Jaques Reifman; Anders Wallqvist
Journal:  J Immunol       Date:  2014-07-30       Impact factor: 5.422

Review 6.  Immune Responses in Malaria.

Authors:  Carole A Long; Fidel Zavala
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

7.  Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast.

Authors:  Elaine C Vicentin; Kátia S Françoso; Mariana V Rocha; Dmitri Iourtov; Fernanda L Dos Santos; Flávia S Kubrusly; Maria A Sakauchi; Isaias Raw; Francois Nosten; Laurent Rénia; Mauricio M Rodrigues; Bruce Russell; Irene S Soares
Journal:  Infect Immun       Date:  2013-12-30       Impact factor: 3.441

Review 8.  Paths to a malaria vaccine illuminated by parasite genomics.

Authors:  David J Conway
Journal:  Trends Genet       Date:  2015-01-22       Impact factor: 11.639

9.  Low levels of polymorphisms and no evidence for diversifying selection on the Plasmodium knowlesi Apical Membrane Antigen 1 gene.

Authors:  Bart W Faber; Khamisah Abdul Kadir; Roberto Rodriguez-Garcia; Edmond J Remarque; Frederick A Saul; Brigitte Vulliez-Le Normand; Graham A Bentley; Clemens H M Kocken; Balbir Singh
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

10.  Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.

Authors:  Sheetij Dutta; Lisa S Dlugosz; Damien R Drew; Xiaopeng Ge; Xiopeng Ge; Diouf Ababacar; Yazmin I Rovira; J Kathleen Moch; Meng Shi; Carole A Long; Michael Foley; James G Beeson; Robin F Anders; Kazutoyo Miura; J David Haynes; Adrian H Batchelor
Journal:  PLoS Pathog       Date:  2013-12-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.